普拉克索治疗帕金森病临床效果评价

Evaluation of Clinical Efficacy of Pramipexole in the Treatment of Parkinson 's Disease

目的评价普拉克索治疗帕金森病临床效果。方法收取我院30例帕金森病患者,收取时间为2016年1月10日-2017年1月21日,并将帕金森病患者分为两组,对照组(15例患者实施常规药物治疗),观察组(15例患者实施普拉克索治疗)。结果观察组帕金森病患者在综合能力评分、屈曲挛缩能力、疼痛、爬坡能力评分方面均优于对照组(P<0.05)。结论普拉克索能显著改善患者运动症状以及非运动症状,为目前临床治疗帕金森病的首选药物,具有显著的疗效,值得在进一步推广及运用。

Objective To evaluate the clinical effect of pramipexole in thetreatment of Parkinson＇s disease. Methods 30 patients with Parkinson＇s disease were collected from January 10, 2016 to January 21, 2017, and patients with Parkinson＇ s disease were divided into two groups, the control group（15 patients were treated with conventional drugs） and the observation group（15 patients treated with pramipexole）. Results The patients with Parkinson ＇s disease were superior to the control group in terms of comprehensive ability score, flexion contracture ability, pain and climbing ability score（P 〈 0.05）. Conclusion Pramipexole can significantly improve the symptoms of patients with exercise and non-exercise symptoms, for the current clinical treatment of Parkinson ＇s disease drug of choice, has a significant effect. It is worth further promotion and use.